MOTS-c is a mitochondria-derived peptide encoded in the 12S rRNA region of the mitochondrial genome, studied for its roles in metabolic regulation, insulin sensitivity, and longevity. As a relatively recently discovered peptide (first described in 2015), its safety profile is still being characterized in ongoing research. This review summarizes the adverse effects observed in available preclinical and early clinical research.
Research Use Only: This information is for educational and research purposes only. MOTS-c is not FDA-approved for human use. Consult a qualified healthcare professional before any use.
MOTS-c activates AMPK signaling pathways and regulates the folate cycle and de novo purine biosynthesis, leading to improved insulin sensitivity and metabolic flexibility. It also activates the Nrf2 antioxidant pathway, contributing to its cytoprotective effects.
Mild redness, swelling, or discomfort at the injection site are the most commonly reported effects in research subjects receiving subcutaneous administration.
Transient fatigue has been reported in some research subjects, particularly during the initial period of administration as metabolic pathways adapt.
Mild gastrointestinal effects including nausea or stomach discomfort have been reported in some research subjects.
Given MOTS-c's insulin-sensitizing effects, research subjects with diabetes or insulin resistance should be monitored for hypoglycemia, particularly when combined with other glucose-lowering agents.
Mild headaches have been reported in a subset of research subjects.
MOTS-c is a relatively recently discovered peptide and its long-term safety profile is still being characterized. Preclinical studies have demonstrated favorable metabolic effects without significant toxicity. It is not FDA-approved for human use and should only be used in legitimate research settings. Its insulin-sensitizing effects warrant caution in subjects with diabetes.
Preclinical studies have demonstrated favorable metabolic effects without significant toxicity. MOTS-c is not FDA-approved for human use and should only be used in legitimate research settings.
Yes. MOTS-c has insulin-sensitizing effects through AMPK activation. Research subjects with diabetes or insulin resistance should be monitored for hypoglycemia, particularly when combined with other glucose-lowering agents.
MOTS-c may have additive effects with other metabolic peptides such as GLP-1 analogues. Combination use should be approached cautiously in research settings.
Long-term safety data for MOTS-c in humans is limited as it is a relatively recently discovered peptide. Ongoing research is characterizing its safety profile.
Purgo Labs provides research-grade MOTS-c with third-party HPLC and mass spectrometry verification from accredited US laboratories. Every batch ships with a full Certificate of Analysis.
Shop MOTS-c at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.